REPCF RepliCel Life Sciences Inc (CE)

VANCOUVER, BRITISH COLUMBIA--(Marketwired - Jan 9, 2014) - RepliCel Life Sciences Inc. (OTCQB:REPCF)(CNSX:RP) is pleased to announce that its common shares are anticipated to commence trading on the TSX Venture Exchange (the "TSXV") on January 13, 2014 as a Tier 1 issuer. RepliCel will trade under its current trading symbol "RP". To ensure continued and seamless trading for RepliCel's shareholders, RepliCel's common shares will be delisted from the Canadian Securities Exchange at the close of trading on January 10, 2014 and will commence trading on the TSXV at market open on January 13, 2014.

About RepliCel Life Sciences

RepliCel is a clinical stage biopharmaceutical company focused on developing autologous cell therapies. RepliCel Tendon-01 (RCT-01) is a cell therapy for the treatment of chronic tendon injuries. RepliCel Hair-01 (RCH-01) is a cellular treatment for androgenetic alopecia (pattern baldness). Shiseido Company, Limited has an exclusive geographic license for RCH-01 in certain Asian countries including Japan, China and South Korea. Both product candidates are based on RepliCel's innovative technology which utilizes cells isolated from a patient's own healthy hair follicles to address specific cellular deficits. For additional information please visit www.replicel.com.

On Behalf of the Board

RepliCel Life Sciences Inc.

David Hall, President and Chief Executive Officer

Notice Regarding Forward Looking Statements

This press release contains projections and forward-looking statements as that term is defined under applicable securities laws. Statements in this press release that are not purely historical are forward-looking statements, which include statements regarding the date of listing on the TSXV and delisting from the Canadian Securities Exchange. These statements are only predictions and involve known and unknown risks which may cause actual results and RepliCel's plans and objectives to differ materially from those expressed in the forward-looking information, including: unforeseen delays in the listing and delisting of RepliCel's common shares and other factors beyond the Company's control.

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

RepliCel Life SciencesTammey GeorgeDirector of Communications604-248-8696tg@replicel.comwww.replicel.comWestwicke Partners, LLCStefan Loren, Ph.D.Managing Director(443) 213-0507sloren@westwicke.comWestwicke Partners, LLCRobert H. UhlManaging Director(858) 356-5932robert.uhl@westwicke.com

RepliCel Life Sciences (CE) (USOTC:REPCF)
Gráfico Histórico do Ativo
De Mai 2024 até Jun 2024

RepliCel Life Sciences (CE) (USOTC:REPCF)
Gráfico Histórico do Ativo
De Jun 2023 até Jun 2024